One of the first steps in drug design is identifying a target protein or molecule involved in the disease process. This can be done using databases such as the National Center for Biotechnology Information (NCBI) and the Universal Protein Resource (UniProt), which contain information on the structures and functions of proteins.

Once a target protein has been identified, the next step is to search for potential drugs that can bind to and modulate the activity of the protein. This can be done using tools such as the Basic Local Alignment Search Tool (BLAST) and the Protein Data Bank (PDB), which contain information on the structures of proteins and small molecules.

Once potential drug candidates have been identified, the next step is to evaluate their binding ability to the target protein. This is typically done using computational techniques such as molecular docking, which predicts the interactions between the drug and the protein. Molecular docking simulations can help identify the drug’s and the protein’s best binding conformation and evaluate the strength of the binding interactions.

After the binding interactions between the drug and the protein have been evaluated, the next step is to assess the drug’s potential effectiveness in modulating the protein’s activity. This is typically done using molecular dynamics simulations, which can help predict the drug’s effects on the protein’s structure and function.

Finally, once the potential effectiveness of the drug has been evaluated, the next step is to conduct experimental studies to validate the predictions made by the computational models. This can involve in vitro and in vivo studies, which can help to confirm the ability of the drug to bind to and modulate the activity of the target protein.

Overall, the use of computational tools and resources such as NCBI, BLAST, UniProt, PDB, molecular docking, and simulation can greatly facilitate and improve the efficiency of the drug design process. These tools and resources can help researchers to identify potential drug candidates and to evaluate their potential effectiveness in modulating the activity of target proteins.

Canine circovirus (CanineCV) is a deadly pathogen affecting both domestic and wild carnivores, including dogs. No vaccine against CanineCV is available commercially or under clinical trials. In the present study, we have designed a promising multiepitope vaccine (MEV) construct targeting multiple strains of CanineCV. A total of 545 MHCII binding CD4+T cell epitope peptides were predicted from the capsid and replicase protein from each strain of CanineCV. Five conserved epitope peptides among the three CanineCV strains were selected. The final vaccine was constructed using antigenic, nontoxic, and conserved multiple epitopes identified in silico. Further, molecular docking and molecular dynamics simulations predicted stable interactions between the predicted MEV and canine receptor TLR-5. One of the mapped epitope peptides was synthesized to validate antigenicity and immunogenicity. In vivo analysis of the selected epitope clearly indicates CD4+T-cell-dependent generation of antibodies, which further suggests that the designed MEV construct holds promise as a candidate for vaccine against CanineCV.

Read the Full Article on American Chemical Society

Dengue virus (DENV) is an arboviral disease affecting more than 400 million people annually. Only a single vaccine formulation is available commercially and many others are still under clinical trials. Despite all the efforts in vaccine designing, the improvement in vaccine formulation against DENV is very much needed. In this study, we used a roboust immunoinformatics approach, targeting all the four serotypes of DENV to design a multi-epitope vaccine. A total of 13501 MHC II binding CD4+ epitope peptides were predicted from polyprotein sequences of four dengue virus serotypes. Among them, ten conserved epitope peptides that were interferon-inducing were selected and found to be conserved among all the four dengue serotypes. The vaccine was formulated using antigenic, non-toxic and conserved multi epitopes discovered in the in-silico study. Further, the molecular docking and molecular dynamics predicted stable interactions between predicted vaccine and immune receptor, TLR-5. Finally, one of the mapped epitope peptides was synthesized for the validation of antigenicity and antibody production ability where the in-vivo tests on rabbit model was conducted. Our in-vivo analysis clearly indicate that the imunogen designed in this study could stimulate the production of antibodies which further suggest that the vaccine designed possesses good immunogenicity.

Read the Full Article on Frontiers in Immunology